Cancer cells can develop resistance to cisplatin by decreasing the concentration by reducing its inflow through CRT1 (human creatine transporter 1) copper transporters and increasing its outflow through ATP7A (copper transporter P-type ATPase) transporters [86]. This evidence concerns the gene ATP7A and cancer.